

research papers
Structure of yeast 5-aminolaevulinic acid dehydratase complexed with the inhibitor 5-hydroxylaevulinic acid
aSchool of Biological Sciences, University of Southampton, Bassett Crescent East, Southampton
SO16 7PX, England, bSchool of Biological Sciences, Queen Mary, University of London, Mile End Road, London
E1 4NS, England, and cInstitut de Chimie, Université de Neuchâtel, Avenue Bellevaux 51, Case Postale 2,
CH-2007 Neuchatel 7, Switzerland
*Correspondence e-mail: [email protected]
The X-ray structure of the enzyme 5-aminolaevulinic acid dehydratase (ALAD) from yeast complexed with the competitive inhibitor 5-hydroxylaevulinic acid has been determined at a resolution of 1.9 Å. The structure shows that the inhibitor is bound by a Schiff-base link to one of the invariant active-site lysine residues (Lys263). The inhibitor appears to bind in two well defined conformations and the interactions made by it suggest that it is a very close analogue of the substrate 5-aminolaevulinic acid (ALA).
PDB reference: 5-aminolaevulinic acid dehydratase, 1w31, r1w31sf
1. Introduction
The enzyme 5-aminolaevulinic acid dehydratase (ALAD, also known as porphobilinogen
synthase; EC 4.2.1.24) catalyses an early step in the biosynthesis of ; Jordan, 1991
, 1994
; Warren & Scott, 1990
; Jaffe, 1995
, 2003
). Subsequent enzymes in the pathway cyclize four of these PBG molecules to make the
core tetrapyrrole framework uroporphyrinogen III, which undergoes various modifications
to form a variety of essential metallo-prosthetic groups, including haem, chlorophyll
and the cobalamins. ALAD enzymes share a high degree of sequence identity, contain
about 350 amino acids per subunit and are usually octameric. In humans, hereditary
deficiencies in ALAD give rise to the rare disease Doss porphyria (Doss et al., 1979
) and the exquisite sensitivity of the human enzyme to inhibition by lead ions is
a major causative factor in acute lead poisoning (Simons, 1995
; Warren et al., 1998
).
![]() |
Figure 1 The reaction catalysed by 5-aminolaevulinic acid dehydratase (ALAD). Two molecules of 5-aminolaevulinic acid (ALA) are condensed to form the pyrrole porphobilinogen (PBG). |
The X-ray structures of ALADs from several species have been determined and several
inhibitor complexes have been studied (Erskine, Senior, Awan et al., 1997; Erskine, Newbold et al., 1999
, 2001
; Erskine, Norton et al., 1999
; Frankenberg et al., 1999
; Mills-Davies, 2001
; Erskine, Coates et al., 2001
). In these structures, the enzyme is a homo-octamer with each subunit adopting a
(β/α)8 or TIM-barrel fold with an N-terminal arm which in yeast ALAD is 39 residues in length
(Fig. 2
). Within the octamer, subunits form dimers in which each subunit has its N-terminal
arm wrapped around the barrel of the other monomer. The octamers result from side-by-side
packing of the closely associated dimers, giving a in which all eight active sites are oriented towards the outer surface and are independent.
The active site of each subunit is located in a pronounced cavity formed by loops
at the C-terminal ends of the β-strands forming the TIM barrel. Recently, evidence has been found for hexameric quaternary
forms of some ALADs (Breinig et al., 2003
; Bollivar et al., 2004
).
![]() |
Figure 2 (a) A ribbon diagram of the TIM-barrel fold of the ALAD monomer with its pronounced N-terminal arm and two active-site lysines shown in ball-and-stick representation. (b) The assembly of ALAD monomers (coloured differently) to form dimers and (c) the organization of the functional ALAD octamer. This figure and others similar were prepared using the programs MOLSCRIPT (Kraulis, 1991 ![]() ![]() |
At the base of the active site are two lysine residues (210 and 263 in yeast ALAD),
one of which (Lys263) is known to form a Schiff-base link to the first molecule of
substrate that binds to the active site (Jordan & Gibbs, 1985; Gibbs & Jordan, 1986
). Single-turnover experiments with labelled ALA have shown that the substrate bound
to Lys263 is incorporated into the propionic acid side, or P-side, of the product
PBG, whereas the second substrate molecule forms the acetic acid side, or A-side,
of PBG (see Fig. 1
). Thus, catalysis was shown to proceed by formation of a Schiff-base link at the
P-site between the 4-keto group of substrate ALA and an invariant lysine residue,
equivalent to Lys263 in yeast ALAD.
Recently, the structures of several ALADs complexed with the inhibitors 4,7-dioxosebacic
acid and 5-fluorolaevulinic have been solved at high resolution (Erskine, Coates et al., 2001; Kervinen et al., 2001
; Frère et al., 2002
). Intriguingly, these inhibitors form two at the active site involving Lys210 as well as Lys263 in yeast ALAD numbering. The
structural evidence that both invariant lysines form with some inhibitors suggests that catalysis involves a double Schiff-base mechanism.
In many ALADs, an active-site zinc ion has been implicated in the catalytic mechanism
and is thought to act on substrate bound to the A-site. The zinc-binding site is formed
by the following residues in yeast ALAD: Cys133, Cys135 and Cys143. In contrast, plant
and some bacterial ALADs require magnesium and lack the triple-cysteine sequence motif,
which is replaced by other amino acids (predominantly aspartate residues) that were
thought likely to coordinate an active-site magnesium ion (Boese et al., 1991). However, no electron density for an active-site magnesium has been found in crystal
structures of several of these ALADs (Frankenberg et al., 1999
; Coates et al., 2004
) and there is evidence that the enzyme from some species is completely metal-independent
(Bollivar et al., 2004
). Thus, it is likely that any apparent magnesium dependence probably arises from
the enzyme's allosteric metal-binding site at the subunit interface, which was first
characterized in the Escherichia coli enzyme (Erskine, Norton et al., 1999
). A more detailed description of the metal requirement of ALADs is given in Jaffe
(2003
).
We have analysed the structures of ALADs in which the active site is occupied by various
inhibitors and all were found to form a Schiff base with Lys263 (Erskine, Newbold
et al., 2001). In addition, the structure of substrate (ALA) bound in this site has been determined
(Erskine, Newbold et al., 2001
). The structure of this complex was obtained by crystallizing partially purified
yeast ALAD and ALA was found to be covalently bound as a Schiff base to Lys263 at
the P-site. The structure of a putative intermediate resembling covalently bound product
has also been determined by co-crystallizing the yeast enzyme in the presence of added
substrate ALA (Erskine et al., 2003
). We now report on the high-resolution X-ray structure of the inhibitor 5-hydroxylaevulinic
acid (Fig. 3
), which is a close analogue of the substrate ALA, bound to the yeast ALAD enzyme.
![]() |
Figure 3 The chemical formula of the ALAD inhibitor 5-hydroxylaevulinic acid. |
2. Materials and methods
Recombinant yeast ALAD was expressed and purified as described previously (Senior
et al., 1996; Erskine, Senior, Awan et al., 1997
). Crystals of yeast ALAD with 5-hydroxylaevulinic acid bound were obtained by co-crystallizing
the enzyme in the presence of the inhibitor. The hanging-drop vapour-diffusion method
was used with 5-hydroxylaevulinic acid present at a concentration of 10 mM and enzyme present at a concentration of 2 mg ml−1. Apart from the presence of inhibitor, the crystallization conditions (2–10% PEG
6000, 200 mM Tris–HCl pH range 7.0–8.0, 6 mM β-mercaptoethanol and 70 µM zinc sulfate) are otherwise identical with those used to crystallize the native enzyme
(Erskine, Senior, Maignan et al., 1997
). Crystals of the complex, which appeared within 3–4 weeks, belong to I422, with unit-cell parameters a = b = 102.6, c = 168.4 Å. The crystals were flash-cooled in liquid ethane and X-ray data were collected
at ESRF (Grenoble) using the ID29 beamline with the crystal maintained at a temperature
of 100 K using an Oxford Cryosystems cooler. The data were processed using MOSFLM (Leslie, 1992
) and the CCP4 suite (Collaborative Computational Project, Number 4, 1994
). The structure was refined using SHELX (Sheldrick & Schneider, 1997
) and the program RESTRAIN (Haneef et al., 1985
) was used for of translation–libration–screw (TLS) tensors. Graphical rebuilding was performed
using TURBO-FRODO (Bio-Graphics, Marseille, France) running on Silicon Graphics (SGI) computers.
3. Results and discussion
5-Hydroxylaevulinic acid (Fig. 3) is a competitive inhibitor of ALAD enzymes, typically with Ki values of 0.25 mM (Neier, 1997
). The initial difference map for yeast ALAD co-crystallized with 5-hydroxylaevulinic
acid showed convincing electron density for the inhibitor bound as a Schiff-base complex
with one of the invariant active-site lysines (Lys263) in the P-site of the enzyme.
The ligand was built into the density accordingly and the structure of the complex
refined for several cycles after each round of manual rebuilding. The final electron-density
map at a resolution of 1.9 Å is shown in Fig. 4
(a), where it can be seen that the inhibitor adopts two conformations on binding to
the enzyme. This interpretation was partly based on the finding that most inhibitor
complexes of yeast ALAD analysed previously at high resolution were found to exhibit
similar disorder in the bound conformation of the inhibitor itself and the side chain
of Lys263 to which the inhibitors are attached (Erskine, Newbold et al., 2001
). Evidence for the occurrence of two conformations was provided by refining the structure
with the inhibitor built in one conformer alone, which yielded strong positive difference
density for the other conformer (see Fig. 4
b). of the occupancy of the two conformers yielded values of 52 and 48%, suggesting that
the inhibitor binds with equal preference for both of the conformations. The atoms
of the bound inhibitor have a mean isotropic B factor of 44.9 Å2, which is comparable with the B factors of the entire complex (mean Biso = 49.27 Å2), confirming that the inhibitor has bound to the majority of the enzyme molecules
forming the crystal. This presumably reflects the buried state of the inhibitor, which
is covered by the enzyme's active-site flap (residues 215–235). These B factors appear to be rather high for a structure refined at 1.9 Å resolution and
we presume that this is an effect of the TLS since lower values were obtained when the structure was refined by conventional means
only, e.g. the mean Biso for the complex was 39.6 Å2, a value which is closer to the Wilson plot B factor of 33.5 Å2.
![]() |
Figure 4 (a) The structure of the inhibitor 5-hydroxylaevulinic acid (labelled OHLA) bound in two conformations to one of the active-site lysines (Lys263) of yeast ALAD. The structure has been refined at 1.9 Å resolution and the corresponding electron density, contoured at 1.0 r.m.s., is shown as purple lines. The active-site zinc ion is shown on the lower right. (b) The same view of the bound inhibitor but showing only one conformation and the resulting positive difference density contoured at 4.5 r.m.s. (shown in magenta) indicating the presence of the other conformer. |
The electron density for the inhibitor is good except for the C-2 position: an effect
common to other P-site ligands which exhibit disordered binding, e.g. the substrate ALA and laevulinic acid (Erskine, Newbold et al., 1999, 2001
; Erskine, Coates et al., 2001
). The electron density for the amino acids surrounding the inhibitor in the P-site
is very good. In contrast, a number of the amino-acid side chains making up the unoccupied
A-site have much poorer electron density. However, it has been shown that these become
dramatically more ordered in the presence of inhibitors which occupy the A-site, e.g. 4,7-dioxosebacic acid (Erskine, Coates et al., 2001
).
The final structure, which was refined using data between 44.3 and 1.9 Å, has an R factor of 18.95% and an Rfree of 24.93% (see Table 1). of the TLS tensors for the TIM-barrel and arm domains gave a significant improvement
in Rfree of over 8%. The final structure has 89.7% of its residues within the `most favoured'
regions of the Ramachandran plot by the PROCHECK criteria (Laskowski et al., 1993
) and 9.6% of residues within the so-called `additional allowed' boundary. No residues
are in the disallowed regions. The temperature factors are reasonable except for a
few residues in the active-site flap (most notably 228–230), where the electron density
remains poor despite extensive efforts to rebuild these residues throughout the process. Nonetheless, the electron density for the active-site loop in this complex
is substantially better than that of the native enzyme.
|
The active site of ALAD is located in a large cavity at the C-terminal end of the
eight-stranded all-parallel β-barrel. It involves two invariant lysine residues (263 and 210 in yeast ALAD), as
well as a zinc ion which is coordinated by three cysteine residues numbered 133, 135
and 143 in the yeast enzyme. The inhibitor in this study forms a Schiff base with
Lys263 and is held in the P-site of the enzyme. The C-5 hydroxyl group of the inhibitor
forms a strong hydrogen bond with the —NH2 side chain of the other invariant active-site lysine (Lys210) in one conformer. Whilst
the inhibitor appears to bind in two conformations in the P-site, in both of these
conformers the C-5 hydroxyl group interacts with the side chains of Asp131 and Ser179,
which are strongly conserved and have been implicated in the mechanism by site-directed
mutagenesis (Shoolingin-Jordan et al., 2002). The same interactions have been observed for the C-5 amino group of substrate ALA
when bound to the P-site of the enzyme (Erskine, Newbold et al., 2001
). The C-5 hydroxyl group also forms a hydrogen bond to the water molecule datively
bound to the active-site zinc ion and the C-5 amino group of substrate ALA likewise
also forms this interaction (Erskine, Newbold et al., 2001
). The aliphatic parts of the inhibitor and substrate ALA (C-2 to C-5) reside in a
hydrophobic pocket formed mainly by aromatic side chains of residues Phe89, Tyr216,
Phe219, Tyr287 and Val289. Like ALA, the C-1 carboxyl group of hydroxylaevulinic acid
forms hydrogen bonds with the side chains of Ser290 and Tyr329 in both of the bound
conformers. Other hydrogen bonds are formed with the side chain of Tyr287 and the
main-chain NH of Ser290 in one of the conformers only.
The A-site in this complex is a solvent-filled cavity bounded on one side by the P-site
5-hydroxylaevulinic acid molecule and on the other by two arginine residues (220 and
232) which are strongly conserved and are thought to interact with the carboxyl of
A-side substrate. Evidence for this was provided by bound structures of the inhibitors
4,7-dioxosebacic acid and 5-fluorolaevulinic acid, which occupy the A-site and P-site
(Erskine, Coates et al., 2001; Kervinen et al., 2001
; Frère et al., 2002
). A major part of the A-site is formed by the zinc ion held by the side chains of
three cysteines. As mentioned above, there is a solvent molecule bound to the zinc
ion that is within hydrogen-bonding distance of the amino group of P-side ALA. It
has been speculated that this solvent molecule may actually be a zinc-bound hydroxide
which abstracts a proton from C-3 of A-side ALA as a prerequisite for formation of
the C—C bond between the two substrates (Erskine, Norton et al., 1999
).
The current study shows that 5-hydroxylaevulinic acid appears in structural terms to be an exceptionally good analogue of the substrate ALA; both bind by making almost exactly the same interactions. The fact that the C-5 hydroxyl binds in the same position as the C-5 amino group of ALA suggests that the charge of the C-5 substituent does not have a great effect on its binding mode. The lower polarity of the hydroxylaevulinic acid compared with substrate ALA might also be expected to increase its bio-availability as an inhibitor of tetrapyrrole biosynthesis, possibly with in vivo applications.
Footnotes
‡Current address: Neutron Diffraction Group, Los Alamos National Laboratory, New Mexico, USA.
Acknowledgements
We gratefully acknowledge the financial support of the Biotechnology and Biological Sciences Research Council (BBSRC, UK) and the European Synchrotron Radiation Facility (Grenoble, France) for beam time.
References
Boese, Q. F., Spano, A. J., Li, J. M. & Timko, M. P. (1991). J. Biol. Chem. 266, 17060–17066. PubMed CAS Web of Science Google Scholar
Bollivar, D. W., Clauson, C., Lighthall, R., Forbes, S., Kokona, B., Fairman, R.,
Kundrat, L. & Jaffe, E. K. (2004). BMC Biochem. 5, 17. Google Scholar
Breinig, S., Kervinen, J., Stith, L., Wasson, A. S., Fairman, R., Wlodawer, A., Zdanov,
A. & Jaffe, E. K. (2003). Nature Struct. Biol. 10, 757–763. Web of Science CrossRef PubMed CAS Google Scholar
Coates, L., Beaven, G., Erskine, P. T., Beale, S. I., Avissar, Y. J., Gill, R., Mohammed,
F., Wood, S. P., Shoolingin-Jordan, P. & Cooper, J. B. (2004). J. Mol. Biol. 342, 563–570. Web of Science CrossRef PubMed CAS Google Scholar
Collaborative Computational Project, Number 4 (1994). Acta Cryst. D50, 760–763. CrossRef IUCr Journals Google Scholar
Doss, M., Von-Tieperman, R., Schneider, J. & Schmid, H. (1979). Klin. Wochenschr. 57, 1123–1127. CrossRef CAS PubMed Web of Science Google Scholar
Erskine, P. T., Coates, L., Butler, D., Youell, J., Brindley, A. A., Wood, S. P.,
Warren, M. J., Shoolingin-Jordan, P. M. & Cooper, J. B. (2003). Biochem. J. 373, 733–738. Web of Science CrossRef PubMed CAS Google Scholar
Erskine, P. T., Coates, L., Newbold, R., Brindley, A. A., Stauffer, F., Wood, S. P.,
Warren, M. J., Cooper, J. B., Shoolingin-Jordan, P. M. & Neier, R. (2001). FEBS Lett. 503, 196–200. Web of Science CrossRef PubMed CAS Google Scholar
Erskine, P. T., Newbold, R., Brindley, A. A., Wood, S. P., Shoolingin-Jordan, P. M.,
Warren, M. J. & Cooper, J. B. (2001). J. Mol. Biol. 312, 133–141. Web of Science CrossRef PubMed CAS Google Scholar
Erskine, P. T., Newbold, R., Roper, J., Coker, A., Warren, M. J., Shoolingin-Jordan,
P. M., Wood, S. P. & Cooper, J. B. (1999). Protein Sci. 8, 1250–1256. CrossRef PubMed CAS Google Scholar
Erskine, P. T., Norton, E., Cooper, J. B., Lambert, R., Coker, A., Lewis, G., Spencer,
P., Sarwar, M., Wood, S. P., Warren, M. J. & Shoolingin-Jordan, M. J. (1999). Biochemistry, 38, 4266–4276. Web of Science CrossRef PubMed CAS Google Scholar
Erskine, P. T., Senior, N., Awan, S., Lambert, R., Lewis, G., Tickle, I. J., Sarwar,
M., Spencer, P., Thomas, P., Warren, M. J., Shoolingin-Jordan, P. M., Wood, S. P.
& Cooper, J. B. (1997). Nature Struct. Biol. 4, 1025–1031. CrossRef CAS PubMed Web of Science Google Scholar
Erskine, P. T., Senior, N., Maignan, S., Cooper, J., Lambert, R., Lewis, G., Spencer,
P., Awan, S., Warren, M., Tickle, I. J., Thomas, P., Wood, S. P. & Shoolingin-Jordan,
P. M. (1997). Protein Sci. 6, 1774–1776. CrossRef CAS PubMed Web of Science Google Scholar
Esnouf, R. (1997). J. Mol. Graph. Model. 15, 132. CrossRef PubMed Web of Science Google Scholar
Frankenberg, N., Erskine, P. T., Cooper, J. B., Shoolingin-Jordan, P. M., Jahn, D.
& Heinz, D. W. (1999). J. Mol. Biol. 289, 591–602. Web of Science CrossRef PubMed CAS Google Scholar
Frère, F., Schubert, W. D., Stauffer, F., Frankenberg, N., Neier, R., Jahn, D. & Heinz,
D. W. (2002). J. Mol. Biol. 320, 237–247. Web of Science CrossRef PubMed CAS Google Scholar
Gibbs, P. N. B. & Jordan, P. M. (1986). Biochem. J. 236, 447–451. CrossRef CAS PubMed Web of Science Google Scholar
Haneef, I., Moss, D. S., Stanford, M. J. & Borkakoti, N. (1985). Acta Cryst. A41, 426–433. CrossRef CAS Web of Science IUCr Journals Google Scholar
Jaffe, E. K. (1995). J. Bioenerg. Biomembr. 27, 169–179. CrossRef CAS PubMed Web of Science Google Scholar
Jaffe, E. K. (2003). Chem. Biol. 10, 25–34. Web of Science CrossRef PubMed CAS Google Scholar
Jordan, P. M. (1991). New Comprehensive Biochemistry, Vol. 19, edited by A. Neuberger & L. L. N. Van Deenen, pp. 1–65. Amsterdam: Elsevier.
Google Scholar
Jordan, P. M. (1994). Curr. Opin. Struct. Mol. Biol. 4, 902–911. CrossRef CAS Web of Science Google Scholar
Jordan, P. M. & Gibbs, P. N. B. (1985). Biochem. J. 227, 1015–1020. CAS PubMed Web of Science Google Scholar
Kervinen, J., Jaffe E. K., Stauffer, F., Neier, R., Wlodawer, A. & Zdanov, A. (2001).
Biochemistry, 40, 8227–8236. Google Scholar
Kraulis, P. (1991). J. Appl. Cryst. 24, 946–950. CrossRef Web of Science IUCr Journals Google Scholar
Laskowski, R. A., MacArthur, M. W., Moss, D. S. & Thornton, J. M. (1993). J. Appl. Cryst. 26, 283–291. CrossRef CAS Web of Science IUCr Journals Google Scholar
Leslie, A. G. W. (1992). Jnt CCP4/ESF–EAMCB Newsl. Protein Crystallogr. 26. Google Scholar
Mills-Davies, N. L. (2001). PhD thesis. University of Southampton, UK. Google Scholar
Neier, R. (1997). Electronic Conference on Heterocyclic Chemistry 96 (ECHET 96). https://www.ch.ic.ac.uk/ectoc/echet96/papers/112/index.htm. Google Scholar
Senior, N., Thomas, P. G., Cooper, J. B., Wood, S. P., Erskine, P. T., Shoolingin-Jordan,
P. M. & Warren, M. J. (1996). Biochem. J. 320, 401–412. CAS PubMed Web of Science Google Scholar
Sheldrick, G. M. & Schneider, T. R. (1997). Methods Enzymol. 277, 319–343. CrossRef PubMed CAS Web of Science Google Scholar
Shoolingin-Jordan, P. M., Spencer, P., Sarwar, M., Erskine, P. T., Cheung, K. M.,
Cooper, J. B. & Norton, E. B. (2002). Biochem. Soc. Trans. 30, 584–590. CrossRef PubMed CAS Google Scholar
Simons, T. J. B. (1995). Eur. J. Biochem. 234, 178–183. CrossRef CAS PubMed Web of Science Google Scholar
Warren, M. J., Cooper, J. B., Wood, S. P. & Shoolingin-Jordan, P. M. (1998). Trends Biochem. Sci. 23, 217–221. Web of Science CrossRef CAS PubMed Google Scholar
Warren, M. J. & Scott, A. I. (1990). Trends Biochem. Sci. 15, 486–491. CrossRef CAS PubMed Web of Science Google Scholar
© International Union of Crystallography. Prior permission is not required to reproduce short quotations, tables and figures from this article, provided the original authors and source are cited. For more information, click here.